Vanguard Group Inc. Sells 47,158 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Vanguard Group Inc. decreased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 0.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,907,815 shares of the company’s stock after selling 47,158 shares during the period. Vanguard Group Inc. owned approximately 5.70% of Amneal Pharmaceuticals worth $225,638,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Comerica Bank increased its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares in the last quarter. Spire Wealth Management grew its holdings in shares of Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $42,000. Advisory Services Network LLC bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $50,000. Finally, Bellevue Group AG bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $79,000. Institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of research reports. Truist Financial increased their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Finally, UBS Group started coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Amneal Pharmaceuticals Stock Down 3.8%

AMRX stock opened at $13.20 on Friday. The business has a 50 day moving average price of $12.82 and a two-hundred day moving average price of $12.73. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 34.74 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.02 and a twelve month high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 272.31% and a net margin of 4.01%. On average, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.